- Home
- LILA vs PCRX Comparison
LILA vs PCRX Comparison
Compare LILA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILA
- PCRX
- Stock Information
- Founded
- LILA 2017
- PCRX 2006
- Country
- LILA Bermuda
- PCRX United States
- Employees
- LILA N/A
- PCRX N/A
- Industry
- LILA Cable & Other Pay Television Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LILA Telecommunications
- PCRX Health Care
- Exchange
- LILA Nasdaq
- PCRX Nasdaq
- Market Cap
- LILA 1.1B
- PCRX 1.2B
- IPO Year
- LILA N/A
- PCRX 2011
- Fundamental
- Price
- LILA $6.49
- PCRX $23.22
- Analyst Decision
- LILA Sell
- PCRX Buy
- Analyst Count
- LILA 1
- PCRX 8
- Target Price
- LILA $6.50
- PCRX $28.38
- AVG Volume (30 Days)
- LILA 353.6K
- PCRX 569.8K
- Earning Date
- LILA 08-05-2025
- PCRX 07-29-2025
- Dividend Yield
- LILA N/A
- PCRX N/A
- EPS Growth
- LILA N/A
- PCRX N/A
- EPS
- LILA N/A
- PCRX N/A
- Revenue
- LILA $4,441,000,000.00
- PCRX $702,772,000.00
- Revenue This Year
- LILA $2.45
- PCRX $7.54
- Revenue Next Year
- LILA $3.11
- PCRX $10.78
- P/E Ratio
- LILA N/A
- PCRX N/A
- Revenue Growth
- LILA N/A
- PCRX 3.08
- 52 Week Low
- LILA $4.26
- PCRX $11.16
- 52 Week High
- LILA $10.82
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- LILA 74.59
- PCRX 35.42
- Support Level
- LILA $5.69
- PCRX $22.82
- Resistance Level
- LILA $5.97
- PCRX $24.36
- Average True Range (ATR)
- LILA 0.21
- PCRX 0.69
- MACD
- LILA 0.10
- PCRX -0.12
- Stochastic Oscillator
- LILA 97.28
- PCRX 17.09
About LILA Liberty Latin America Ltd.
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.